Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
NCT Number: NCT06795139
The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02215, United States
This study is about testing a tool called the Trial Enrollment Diversity Dashboard (TEDD) to see if it can help increase diversity in cancer clinical trials, specifically for leukemia. Clinical trials are important for developing new cancer treatments, but not all groups are equally represented in these trials. This can lead to treatments that may not work as well for everyone.
The TEDD tool is designed to give medical professionals feedback on how diverse their patient enrollments are clinical trials. By using this tool, medical professionals can see if they are enrolling a diverse group of patients and make changes if needed.
The study will involve a small group of medical professionals who treat leukemia patients. They will use the TEDD tool and provide feedback on its usability and effectiveness. Study procedures include completion of surveys and usage of the TEDD intervention dashboard.
It is expected that about 12 medical professionals will take part in this research study. Participation in this research study is expected to last about 14 months.
The National Cancer Institute is providing funding for this research study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Medical Professionals:
-≥10% clinical effort (or one ½ day of clinic per week for those working <1 FTE)
Inclusion criteria
Participant Population:
Exclusion criteria
Medical Professionals:
-Listed member of the research team
Exclusion criteria
Participant Population:
-Participants without the diagnoses of interest listed above, participants not seen at the study sites.
A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
Time frame: 12 months
Utilization will be measured as the proportion of quarters where a participant accessed the dashboard divided by the total number of study quarters. Based on 12 participants over 4 three-month quarters, there are a total of 48 person-quarters available for analysis.
Dana-Farber Cancer Institute
Other
Feasibility Pilot of a Trial Enrollment Diversity Dashboard (TEDD)
Acronym: TEDD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03434730
Acute Leukemia, Acute Lymphoblastic Leukemia
New York, United States
View Trial DetailsNCT00701844
Acute Leukemia, Acute Lymphocytic Leukemia
Hackensack, New Jersey, United States
View Trial DetailsNCT07356154
Acute Leukemia, Acute Lymphoblastic Leukemia
Duarte, California, United States
View Trial DetailsNCT07634653
Acute Leukemia, Acute Lymphoblastic Leukemia
Chapel Hill, North Carolina, United States
View Trial Details